GMS Ventures & Investments, Director at Outlook Therapeutics, bought OTLK on Aug 12, 2026
Data as of Oct 16
▲ BUY$2.5M2,525,252 shares at $0.99GMS Ventures & Investments DirectorOTLK Outlook Therapeutics, Inc.
- Traded
- Aug 12, 2026
- Disclosed
- Aug 14, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
OTLK since disclosure
−35.5%
Similar stocks (XLV) since disclosure
+5.6%
XLV — its sector index fund
Change in closing price from Aug 14, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▲ BUYGhiath M. Sukhtian DirectorOTLK Outlook Therapeutics, Inc.$2.5Mdisclosed Aug 14 · filed 2 days after the trade